N
EIKN

Nuveen’s Eikon Therapeutics EIKN Stock Holding History

Nuveen’s Portfolio EIKN Stock Details EIKN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$378K Buy
+28,988
New +$296K ﹤0.01% 3407

Other funds holding EIKN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $526M AUM 175.27% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return
ProShare Advisors
ProShare Advisors Bethesda, Maryland $69.2B AUM 41.24% 1-Year Est. Return

Nuveen's EIKN Position: Q2 2026 in Review

Nuveen opened a new position in Eikon Therapeutics (EIKN) in Q2 2026: 28,988 shares worth $378K. The stake represents ﹤0.01% of the portfolio and ranks #3407 among its holdings.

29 funds tracked by Wall St. Rank hold EIKN as of Q2 2026.

  • Nuveen held 28,988 shares of Eikon Therapeutics worth $378K as of Q2 2026.
  • Eikon Therapeutics was a new Nuveen position in Q2 2026.
  • Eikon Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #3407 holding.
  • 29 funds tracked by Wall St. Rank held Eikon Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.